Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168607 | 0.77 | POLB (0.39) | POLBCASP6PTGS2CYP2C9CYP2C19 | |
| SCHEMBL12863013 | 0.77 | PTGS2 (0.42) | POLBCASP6PTGS2 | |
| SCHEMBL442707 | 0.73 | ATM (0.50) | POLBCASP6ALOX5 | |
| SCHEMBL1291771 | 0.72 | PTGS1 (0.38) | POLBCASP6PTGS1PTGS2CYP1A2 | |
| SCHEMBL1169205 | 0.70 | KMT2A (0.44) | POLB | |
| SCHEMBL1663351 | 0.68 | ALDH1A1 (0.41) | PTGS1PTGS2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13341117 | 0.67 | PTGS1 (0.43) | POLBPTGS1PTGS2CYP1A2CYP2C9 | |
| SCHEMBL3340685 | 0.66 | POLB (0.33) | POLBCASP6 | |
| SCHEMBL3093874 | 0.64 | POLB (0.41) | POLBCASP6PTGS1CYP1A2CYP2C9 | |
| SCHEMBL11812116 | 0.63 | HRH4 (0.40) | POLBPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186918-A1 | Triazole Compounds as Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | POLB 2092/4885CASP6 1046/4885PTGS1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.